Nutranomics Completes GenEpic™ Prostate Cancer Human Clinical Study Due Diligence Review
DRAPER, Utah, Nov. 11, 2013 /PRNewswire/ -- Nutranomics, Inc. (OTCBB: NNRX) (OTCQB: NNRX) ("Nutranomics" or the "Company") is pleased to provide this update regarding the GenEpic™ prostate cancer human clinical study that is currently underway. Nutranomics has previously announced a non-binding Letter of Intent with Genesar Nutraceuticals, LLC ("Genesar") with the intent of completing a licencing agreement to market and distribute GenEpic™ globally.
"We are very pleased to report that our science and legal teams have recently been able to conduct a full due diligence review of the most recent progress and data from the current IRB reviewed GenEpic™ human clinical study being conducted at OH Research Group in Salt Lake City, Utah," stated Nutranomics' CEO Dr. Tracy K. Gibbs. "The one-year study is now in its 11th month and we are all very encouraged by the positive results. We look forward to the conclusion of the current study within the next 60 days and completing the planned acquisition of the GenEpic™ distribution rights."
The GenEpic™ human clinical study on prostate cancer treatment and recovery has been reviewed by an Institutional Review Board (IRB). The IRB reviews plans for all research involving human subjects. The Food and Drug Administration (FDA) and the Office for Human Research Protections (OHRP) (part of the National Institutes of Health) set the guidelines and regulations governing human subjects research and IRBs.
Dr. Gibbs concluded, "Because GenEpic™ is intended to act as an ATP inhibitor, we are hopeful that the study will show that it is effective for treating prostate cancer, and that it could also be effective to treat many other types of rapidly growing cancers. Once this study is complete, we anticipate starting new research on breast cancer treatment and potentially other forms of the disease."
GenEpic™ is a natural therapeutic formula containing 70 vitamins and minerals, 32 herbs, and 16 enzymes and phytonutrients, and formulated by a respected team of five scientists and natural medicine experts, including Dr. Gibbs. GenEpic™ is currently the subject of an IRB reviewed human clinical study on prostate cancer treatment and recovery that is expected to be completed within the next 60 days.
The potential completion of a GenEpic™ distribution licence is subject to the parties entering into a definitive agreement. There can be no assurance that any transaction will be completed as proposed or at all.
Nutranomics is a publicly traded company engaged in research and development of nutritional food products. In 1997, Nutranomics produced and branded its own product line, and began to sell to the retail outlets and to the public. Nutranomics has also produced formulas for hundreds of other companies. Nutranomics' mission is to increase human health and longevity through education and self-awareness. The Company has sales representatives throughout North America and Asia.
For further information regarding Nutranomics, Inc., please contact our investor relations representatives at email@example.com or call toll-free (888) 616-3999.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements." Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include the Company's intent to acquire a GenEpic™ distribution licence, the completion human clinical trials, and conducting future GenEpic™ research regarding other forms of cancer. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products and operating as a development stage company, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law, including the securities laws of the United States. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
SOURCE Nutranomics, Inc.